BrainChild Bio, Inc. logo

BrainChild Bio, Inc.

brainchildbio.com

BrainChild Bio develops CAR T-cell therapies for central nervous system tumors, prioritizing pediatric brain cancers such as diffuse intrinsic pontine glioma and extending its pipeline to adult tumors including glioblastoma and brain metastases. It aims to create safe and effective treatment options for children and adults with incurable brain tumors.

Facts

Sectors
Biotechnology Research
Employees
11–50
Stage
Series A
Founders
Michael Jensen, MD

Is this your organization? Claim it

Jacob Colker announces Seattle startups score major wins: Stoke Space $1B raise, BrainChild Bio $116M, Nuance Labs $50M, Helion expands

A roundup by Jacob Colker highlights major Seattle-area tech and biotech funding and growth: Stoke Space raised $1B (now $2.3B) for reusable rockets, BrainChild Bio $116M for a CAR-T DIPG trial, General Robotics offers rapid robot deployment, Helion expands amid fusion commercialization with 800+ employees, and Nuance Labs raised $50M for multimodal AI.

See all 17 stories, episodes and videos about BrainChild Bio, Inc..

People

  • Michael Jensen
    Michael Jensen Founder, Chief Scientific Officer
  • Steven Brugger Executive, Chief Executive Officer

Online